296 related articles for article (PubMed ID: 19588120)
1. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.
Jonasson JM; Ljung R; Talbäck M; Haglund B; Gudbjörnsdòttir S; Steineck G
Diabetologia; 2009 Sep; 52(9):1745-54. PubMed ID: 19588120
[TBL] [Abstract][Full Text] [Related]
2. Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation.
Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
Acta Oncol; 2011 Jun; 50(5):685-93. PubMed ID: 21506898
[TBL] [Abstract][Full Text] [Related]
3. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM;
Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
[TBL] [Abstract][Full Text] [Related]
4. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
5. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
6. Combined randomised controlled trial experience of malignancies in studies using insulin glargine.
Home PD; Lagarenne P
Diabetologia; 2009 Dec; 52(12):2499-506. PubMed ID: 19756478
[TBL] [Abstract][Full Text] [Related]
7. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
Juhaeri J; Gao S; Dai WS
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
Lind M; Fahlén M; Eliasson B; Odén A
Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
[TBL] [Abstract][Full Text] [Related]
10. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
[TBL] [Abstract][Full Text] [Related]
11. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
12. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
[TBL] [Abstract][Full Text] [Related]
13. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.
Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M
Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665
[TBL] [Abstract][Full Text] [Related]
14. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
Fagot JP; Blotière PO; Ricordeau P; Weill A; Alla F; Allemand H
Diabetes Care; 2013 Feb; 36(2):294-301. PubMed ID: 22966091
[TBL] [Abstract][Full Text] [Related]
15. Risk of breast cancer by individual insulin use: an international multicenter study.
Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine and incidence of cancer--an ongoing debate.
Hermanns N; Kulzer B
J Diabetes Sci Technol; 2010 Mar; 4(2):497-8. PubMed ID: 20307414
[No Abstract] [Full Text] [Related]
17. Insulin glargine and risk of cancer: a meta-analysis.
Du X; Zhang R; Xue Y; Li D; Cai J; Zhou S; Huang Z; Yu R; Liu Y
Int J Biol Markers; 2012 Oct; 27(3):e241-6. PubMed ID: 22865296
[TBL] [Abstract][Full Text] [Related]
18. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study.
But A; De Bruin ML; Bazelier MT; Hjellvik V; Andersen M; Auvinen A; Starup-Linde J; Schmidt MK; Furu K; de Vries F; Karlstad Ø; Ekström N; Haukka J
Diabetologia; 2017 Sep; 60(9):1691-1703. PubMed ID: 28573394
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.
Chang CH; Toh S; Lin JW; Chen ST; Kuo CW; Chuang LM; Lai MS
PLoS One; 2011; 6(6):e21368. PubMed ID: 21738645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
